To our knowledge, this is the first study to provide evidence that TNFAIP3-targeted agents could mitigate COPD progression (via NF-κB suppression) and insomnia pathophysiology (via cytokine-mediated SCN modulation) [29]. The gene discussed is NFKB1; the disease is insomnia measurement.